Compositions of boswellic acids derived from Boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
May 4, 2006
filing date -
Apr 30, 1999
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
A method of treatment of lymphoproliferative and autoimmune disorders with a new composition of four boswellic acids including .beta.-boswellic acid, 3-O-acetyl-.beta.-boswellic acid, 11-keto-.beta.-boswellic acid, and 3-O-acetyl-11-keto-.beta.-boswellic acid. Boswellic acids of invention have been obtained in a novel industrial process from the gum resin of Boswellia serrata tree, providing standardized composition which inhibits DNA, RNA and protein synthesis of the target cell without cytotoxic effects. The composition of invention provides advantage of irreversible cytostatic therapy, equivalent to biological effects of a cytotoxic therapy without killing body cells.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully